Weighted-Average Shares Outstanding (Diluted): The number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options, sourced from the company 10-K or 10-Q SEC reports.
Fate Therapeutics, Inc. (FATE) had Weighted-Average Shares Outstanding (Diluted) of 119.00M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$1.74M |
|
$-32.25M |
|
-- |
|
$1.74M |
|
$36.48M |
|
$-34.73M |
|
$2.48M |
|
$-32.25M |
|
$-32.25M |
|
$-32.25M |
|
$-32.25M |
|
$-32.25M |
|
$-32.25M |
|
$-34.73M |
|
$-32.32M |
|
119.00M |
|
|
Weighted-Average Shares Outstanding (Diluted) |
119.00M |
$-0.27 |
|
$-0.27 |
|
| Balance Sheet Financials | |
$221.25M |
|
$59.48M |
|
$122.42M |
|
$343.67M |
|
$28.11M |
|
-- |
|
$81.49M |
|
$109.61M |
|
$234.06M |
|
$234.07M |
|
$234.07M |
|
115.34M |
|
| Cash Flow Statement Financials | |
$-82.77M |
|
$83.54M |
|
$3.80M |
|
$46.28M |
|
$50.85M |
|
$4.57M |
|
$19.40M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.87 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-1995.12% |
|
-1995.12% |
|
-- |
|
-1852.38% |
|
-1852.38% |
|
$-87.41M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
2.55 |
|
35.26 |
|
-13.78% |
|
-13.78% |
|
-9.38% |
|
-13.78% |
|
$2.03 |
|
$-0.73 |
|
$-0.70 |
|